Suppr超能文献

血尿在 podocytopathies 中的意义。

The Significance of Hematuria in Podocytopathies.

机构信息

Department of Pediatrics, Division of Nephrology, University of Michigan, Ann Arbor, Michigan.

Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan.

出版信息

Clin J Am Soc Nephrol. 2024 Jan 1;19(1):56-66. doi: 10.2215/CJN.0000000000000309. Epub 2023 Sep 21.

Abstract

BACKGROUND

Hematuria is frequently present in podocytopathies, but its significance and prognostic value is not well described in these proteinuric kidney diseases. This study describes the prevalence and association between hematuria and kidney-related outcomes in these disorders.

METHODS

Hematuria was assessed at the initial urinalysis in participants with the following podocytopathies-membranous nephropathy, minimal change disease, and FSGS-in the Nephrotic Syndrome Study Network and Cure Glomerulonephropathy cohorts with >24 months of follow-up. Multivariable Cox proportional hazards models were fit for time to composite outcome (kidney failure or 40% decline in eGFR and eGFR <60 ml/min per 1.73 m 2 ) and proteinuria remission (urine protein-to-creatinine ratio [UPCR] <0.3 mg/mg).

RESULTS

Among the 1516 adults and children in the study, 528 participants (35%) had FSGS, 499 (33%) had minimal change disease, and 489 (32%) had membranous nephropathy. Median (interquartile range) time from biopsy until the initial study urinalysis was 260 (49-750) days, and 498 participants (33%) were positive for hematuria. Participants with hematuria compared with those without were older (37 [16-55] versus 33 [12-55] years), more likely to have an underlying diagnosis of membranous nephropathy (44% versus 27%), had shorter time since biopsy (139 [27-477] versus 325 [89-878] days), and had higher UPCR (3.8 [1.4-8.0] versus 0.9 [0.1-3.1] g/g). After adjusting for diagnosis, age, sex, UPCR, eGFR, time since biopsy, and study cohort, hematuria was associated with a higher risk of reaching the composite outcome (hazard ratio, 1.31; 95% confidence interval, 1.04 to 1.65; P value, 0.02) and lower rate of reaching proteinuria remission (hazard ratio, 0.80; 95% confidence interval, 0.65 to 0.98; P value, 0.03).

CONCLUSIONS

Hematuria is prevalent among participants with the three podocytopathies and is significantly and independently associated with worse kidney-related outcomes, including both progressive loss of kidney function and remission of proteinuria.

摘要

背景

血尿在足细胞病中经常出现,但在这些蛋白尿性肾脏疾病中,其意义和预后价值尚未得到很好的描述。本研究描述了这些疾病中血尿的患病率以及与肾脏相关结局之间的关联。

方法

在 Nephrotic Syndrome Study Network 和 Cure Glomerulonephropathy 队列中,对存在以下足细胞病的参与者(膜性肾病、微小病变性肾病和 FSGS)进行初始尿液分析时,评估血尿,这些参与者的随访时间超过 24 个月。采用多变量 Cox 比例风险模型来拟合复合结局(肾衰竭或 eGFR 下降 40%和 eGFR<60 ml/min/1.73 m 2 )和蛋白尿缓解(尿蛋白与肌酐比值[UPCR]<0.3 mg/mg)的时间。

结果

在这项研究中的 1516 名成人和儿童中,528 名参与者(35%)患有 FSGS,499 名(33%)患有微小病变性肾病,489 名(32%)患有膜性肾病。从活检到初始研究尿液分析的中位(四分位距)时间为 260(49-750)天,498 名参与者(33%)的血尿为阳性。与无血尿的参与者相比,血尿的参与者年龄更大(37[16-55]岁与 33[12-55]岁),更有可能被诊断为膜性肾病(44%与 27%),活检后时间更短(139[27-477]天与 325[89-878]天),且 UPCR 更高(3.8[1.4-8.0]g/g 与 0.9[0.1-3.1]g/g)。在校正诊断、年龄、性别、UPCR、eGFR、活检后时间和研究队列后,血尿与复合结局的风险更高相关(风险比,1.31;95%置信区间,1.04 至 1.65;P 值,0.02),达到蛋白尿缓解的概率更低(风险比,0.80;95%置信区间,0.65 至 0.98;P 值,0.03)。

结论

血尿在患有三种足细胞病的参与者中较为常见,与更差的肾脏相关结局显著相关,包括肾功能进行性丧失和蛋白尿缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d08/10843204/9e7e2056c921/cjasn-19-056-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验